The significant outperformance of Vertex Pharmaceuticals over the past decade, as highlighted by its 19.99% average annual return and the substantial growth of an initial $100 investment into $605.57, underscores the company's strong market position and potential for continued growth. This historical performance, coupled with a current market capitalization of $105.03 billion, suggests a positive outlook for VRTX stock in the short term, as investors may be drawn to its proven track record of returns.